These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 8205843)
1. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Tindle RW; Frazer IH Curr Top Microbiol Immunol; 1994; 186():217-53. PubMed ID: 8205843 [No Abstract] [Full Text] [Related]
2. [Immunologic aspects of infections with papillomaviruses. Prospects for a vaccine]. Höpfl R; Heim K Hautarzt; 1996 Oct; 47(10):739-43. PubMed ID: 9036120 [TBL] [Abstract][Full Text] [Related]
3. Immunobiology of papillomavirus infections. Stanley MA J Reprod Immunol; 2001; 52(1-2):45-59. PubMed ID: 11600177 [No Abstract] [Full Text] [Related]
4. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726 [TBL] [Abstract][Full Text] [Related]
5. Use of mature dendritic cells for anti-human papillomavirus peptide-based vaccination in transplant patients. Mariat C; Alamartine E; Sabido O; Berthoux F Transplant Proc; 2002 Nov; 34(7):2836-7. PubMed ID: 12431627 [No Abstract] [Full Text] [Related]
6. Vaccinating women against premature death: summary of an International Workshop, Helsinki, Finland, 10.01.2000. Lehtinen M; Dillner J; Paavonen J Vaccine; 2001 Jan; 19(11-12):1347-52. PubMed ID: 11252250 [No Abstract] [Full Text] [Related]
7. Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine. Halpern AL J Clin Virol; 2000 Oct; 19(1-2):43-56. PubMed ID: 11091147 [TBL] [Abstract][Full Text] [Related]
8. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer]. Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657 [TBL] [Abstract][Full Text] [Related]
9. Immunology of the human papilloma virus in relation to cancer. Wu TC Curr Opin Immunol; 1994 Oct; 6(5):746-54. PubMed ID: 7826530 [TBL] [Abstract][Full Text] [Related]
10. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983 [TBL] [Abstract][Full Text] [Related]
11. [Biology of the papillomavirus infections: V. Vaccine developments]. Seilles E; Riethmuller D; Mougin C Ann Biol Clin (Paris); 1999; 57(5):517-24. PubMed ID: 10518053 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease. Chu NR Expert Opin Biol Ther; 2003 Jun; 3(3):477-86. PubMed ID: 12783616 [TBL] [Abstract][Full Text] [Related]
13. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916 [TBL] [Abstract][Full Text] [Related]